The change of prognosis of 1,492 nonselected patients with multiple myeloma during 60 years in the Middle and partially in the North Moravia region
Authors:
V. Ščudla 1-3; J. Minařík 1,2; J. Bačovský 1-3; T. Pika 1,2; M. Zemanová 1; P. Krhovská 2; T. Szotkowski 2; L. Raida 2; E. Faber 2; K. Indrák 2,3; T. Papajík 2
Authors‘ workplace:
III. interní klinika nefrologická, revmatologická a endokrinologická, LF UP a FN Olomouc
1; Hemato-onkologická klinika LF UP a FN Olomouc
2; I. interní klinika LF UP a FN Olomouc
3
Published in:
Transfuze Hematol. dnes,32, 2026, No. 2, p. 105-125.
Category:
Original Papers
doi:
https://doi.org/10.48095/cctahd202612
Overview
Objectives: To analyze the development of overall survival (OS), early mortality (EM), and 1 , 5 , and 10 year survival from the diagnosis of multiple myeloma (MM) as a result of advances in anti myeloma and supportive treatments in patients from Central and Northern Moravia over six decades, including evaluation of the impact of age on treatment outcomes and disease prognosis. Materials and Methods: A retrospective analysis was conducted on an unselected cohort of 1,492 patients with symptomatic MM treated at the University Hospital in Olomouc between 1959 and 2022. Median OS was estimated using Kaplan-Meier analysis, and EM was defined as death occurring within one year of diagnosis. Results: A significant and sustained increase in median OS was observed across the predefined time intervals, both in the full patient cohort and in the subgroup aged ≤ 65 years, while improvements among patients older than 65 years were largely non significant. In the pre chemotherapy era (1959–1963), when treatment was purely symptomatic, median OS was 8 months for the total cohort, 9 months for those ≤ 65 years, and only 4 months in the > 65-year group. With the introduction of unsystematic MP regimen therapy (1963–1975), median OS increased to 19, 23, and 10 months in the respective age groups. The era of combined polychemotherapy (1976–1995) saw further gains, with median OS reaching 39, 46, and 32 months. From 1996 to 2010, during which high dose therapy with autologous peripheral hematopoietic cell transplantation (VDT ATPKB) was implemented alongside bortezomib, lenalidomide, and pomalidomide, median OS rose to 45 months overall, 60 months for those ≤ 65, and 30 months for patients older than 65. In the most recent period (2011–2022), characterized by the partial introduction of carfilzomib, daratumumab, and ixazomib, these figures further improved to 54, 95, and 36 months, respectively. In transplant eligible patients under 70 years, median OS reached 114 months during 2011–2022, whereas non transplant eligible individuals treated with conventional therapies achieved a median OS of only 56 months. Early mortality decreased most markedly in younger age groups: comparing the earliest period (1959–1963) with 2011–2016, EM fell from 83.3%, 72.7% and 60.0% in the ≤ 60, 61–70, and > 70 age groups to 4.9%, 12.0%, and 38.2%, respectively. Similarly, the proportions of patients surviving at 1, 5 and 10-years post-diagnosis increased substantially between the early (1959–1963) and later (1996–2010) eras. Among those aged ≤ 60 years, survival rose from 16.7%, 0.0%, and 0.0% to 85.6%, 54.3%, and 32.2%; for patients aged 61–70, from 27.3%, 0.0%, and 0.0% to 79.1%, 39.0%, and 15.4%; and among seniors over 70, from 40.0%, 0.0%, and 0.0% to 72.9%, 25.2%, and 6.9%. Conclusion: Over a span of six decades in the evaluated Moravian region, median OS increased nearly sixfold for the entire cohort and up to tenfold in patients aged ≤ 65, while early mortality declined fourfold. There was also a substantial rise in 1 and 5-year survival rates. A strong age dependent relationship with both OS and EM was confirmed, pointing to the urgent need for further refinement of therapeutic strategies, especially for patients over 70.
Keywords:
Multiple myeloma – overall survival – antimyeloma therapy – early mortality – 1-, 5- and 10-years survival – relationship of age and survival
Sources
1. Osgood E. The survival time of patients with plasmocytic myeloma. Cancer Chemother Rep. 1960; 9 : 1–10.
2. Kyle RA. Long-term survival in multiple myeloma. N Engl J Med. 1978; 19 : 314–318.
3. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med. 1994; 330 : 484–489.
4. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111 : 2516–2520. doi: 10.1182/blood-2007-10-116129.
5. Anderson KC. Progress and paradigms in multiple myeloma. Clin Cancer Res. 2016; 22 : 5419–5427. doi: 10.1158/1078-0432.CCR-16-0625.
6. Thorsteinsdottir S, Dickman PW, Landgren O, et al. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica. 2018; 103: e412–e415. doi: 10.3324/haematol.2017.183475.
7. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008; 111 : 2521–2526. doi: 10.1182/blood-2007 - 08-104984.
8. Zhan F, Barlogie B, Mulligan G, et al. High-risk myeloma: a gene expression based risk - stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood. 2008; 111 : 968–969.
9. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012; 120 : 2817–2825.
10. Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012; 119 : 2100–2105.
11. Avet-Loiseau H, Durie BGM, Cavo M, et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia. 2013; 23 : 711–717.
12. San Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open label, phase 3 trial. Lancet Oncol. 2013; 14 : 1055–1066. doi: 10.1016/S1470-2045 (13) 70380-2.
13. Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013; 88 : 360–376. doi org/10.1016/j.mayocp.2013.01.019.
14. Alexanian R, Bergsagel DE, Migliore PJ, Vaughn WK, Howe CD. Melphalan therapy for plasma cell myeloma. Blood 1968; 31 : 1–10.
15. Peest D, Deicher H, Coldwey R, Schmoll HJ, Schedel I. Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP. Eur J Canc Clin Oncol. 1988; 24 : 1061–1067.
16. Oken M, Harrington D, Abramson N, Kyle RA, Knospe W, Glick JH. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide and prednisone in the treatment of multiple myeloma. Results of Eastern Cooperative Oncology Group study E 2479. Cancer. 1997; 79 : 1561–1567.
17. Myeloma Trialist’s Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomised trials. J Clin Oncol. 1998; 16 : 3832–3842.
18. Hjorth M, Holmberg E, Rödjer S, et al. Survival in conventionally treated younger (below 60 years) multiple myloma patients: no improvement during two decades. Eur J Haematol. 1999; 62 : 217–277.
19. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992; 10 : 334–342.
20. Dubost JJ, Ristori JM, Soubrier M, Zbadi K, Bussiere JL, Sauvezie B. Prognosis of multiple myeloma treated with conventional chemotherapy has not improved in 20 years. Rev Med Int. 1996; 17 : 895–900.
21. Harousseau J-L, Attal M, Divine M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of French registry on autologous transplantation in multiple myeloma. Blood 1995; 85 : 3077–3085.
22. Attal M, Harousseau J-L, Stoppa AM, Scotto JJ, Fuzibet G, Rossi JF. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996; 335 : 91–97. doi: 10.1056/NEJM199607113350204.
23. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma up front or rescue treatment. Results of a multicenter sequential randomized clinical trial. Blood. 1998; 92 : 3131–3136.
24. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol. 2010; 28 : 830–834. doi: 10.1200/JCO.2009.25.4177.
25. Palumbo A, Attal M, Roussel M. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overal survival. Clin Cancer Res. 2011; 17 : 1253–1263. doi.org/10.1158/1078-0432.CCR-10-1925.
26. Lokhorst HM, Sonneveld P, Verdonck LF. Intensive treatment for multiple myeloma. Where do we stand? Br J Haematol. 1999; 106 : 18–27.
27. Scudla V, Bacovsky J, Indrak K et al. Results of therapy and changing prognosis of multiple myeloma during the last 40 years in the region of North and Middle Moravia: group of 562 patients. Hematol J. 2003; 4 : 351–357.
28. Ščudla V. Pokroky v léčbě mnohočetného myelomu. Vnitř Lék. 1997; 43 : 529–536.
29. Ludwig H, Bolejack V, Crowley J, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2010; 28 : 1599–1605. doi: 10.1200/JCO. 2009.25.2114.
30. Pulte D, Gondos A, Brenner H. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist. 2011; 16 : 1600–1603. doi: 10.1634/theoncologist.2011-0229.
31. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014; 28 : 1122–1128. doi: 10.1038/leu.2013.313.
32. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. New J Engl J Med. 1999; 341 : 1565–1571.
33. Kumar S, Anderson KC. Drug insight: thalidomide as a treatment for multiple myeloma. Nat Clin Pract Oncol. 2005; 2 : 262–270.
34. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006; 24 : 431–436.
35. Rajkumar SV, Kyle RA, Connor RF. Multiple myeloma: overview of management. UpToDate 2022. www.uptodate.com c 2022.
36. Kyle RA. Five decades of therapy for multiple myeloma: a paradigm for therapeutic models. Leukemia. 2005; 19 : 910–912. doi: 10.1038/sj.leu.2403728.
37. Hájek R, et al. Diagnostika a léčba mnohočetného myelomu. Souhrn doporučení 2018 CMG. Transfuze Hematol Dnes. 2018; 24 (Supp.1): 1–160.
38. Orlowski RZ, Lonial S. Integration of novel agents into the care of patients with multiple myeloma. Clin Cancer Res. 2016; 22 : 5443–5452. doi: 10.1158/1078-0432.CCR-16-0861.
39. Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, et al. From transplant to novel cellular therapies in multiple myeloma: European myeloma network guidelines and future perspectives. Haematologica. 2018; 103 (2): 197–211. doi: 10.3324/haematol.2017.174573.
40. Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017; 389 : 519–527.
41. Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018; 378 : 518–528.
42. Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22 : 1582–1596.
43. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation in myeloma. N Engl J Med. 2017; 376 : 1311–1320. doi: 10.1056/NEJM oa1611750.
44. Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020; 7: e456–e468.
45. Bobin A, Liuu E, Moya N, et al. Multiple myeloma: an overview of the current and novel therapeutic approaches in 2020. Cancers (Basel). 2020; 12 : 2885–2909. doi: 10.3390/cancers 12102885.
46. Gaballa MR, Ma J, Tanner MR, et al. Real-world long term outcomes in multiple myeloma with RVD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma. 2021; 22 : 1–12. doi: 10.1080/10428194.2021.1992763.
47. Voorhees PM, Sborov DW, Laubach J, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patient with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023; 10: e825–e837. doi: 10.1016/S2352-3026 (23) 00217-X.
48. Facon T, Dimopoulos MA, Leleu XP, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024; 391 (17): 1597–1609. doi: 10.1056/NEJM oa240071.
49. Hájek R, Muroňová L, Mihályová J, et al. Nové terapeutické možnosti a trendy v léčbě mnohočetného myelomu. Vnitř.Lék. 2025; 71 : 176–182.
50. Richardson PG, Jacobus SJ, Weller EA, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022; 387 : 132–147. doi: 10.1056/NEJMoa2204925.
51. Usmani SZ, Facon T, Hungria V, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nature Med. 2025; 31 : 1195–1202.
52. Kaplan DA. Multiple myeloma: top 10 advances in the past 10 years. Targ Ther Oncol. 2022; 11 : 70.
53. Langren O, Iskander K. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Int Med. 2017 : 281 : 365–382. doi: 10.1111/joim.12590.
54. Špička I. Biologická léčba mnohočetného myelomu v roce 2021. Acta Med. 2022; 11 : 84–87.
55. Castella M, de Larrea CF, Martín-Antonio B. Immunotherapy: a novel era of promising treatments for multiple myeloma. Int J Mol Sci. 2018; 19 : 3613. doi: 10.3390/ijms19113613.
56. Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019; 37 : 1228–1263. doi: 10.1200/JCO.18.02096.
57. Dimopoulos MA, Moreau P, Terpos E, et al. EHA guidelines committee. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32 : 309–322. doi: 10.1016/j.annonc.2020.11.014.
58. NCNN clinical practice guidelines in oncology. Multiple myeloma, version 4.2022. Accessed Fabruary 12, 2022. https: //bit.ly/3h865Zj
59. Gonsalves WI, Godby K, Kumar SK, Costa LJ. Limiting early mortality: do’s and don’ts in the management of patients with newly diagnosed multiple myeloma. Am J Hematol. 2016; 91 : 101–108. doi: 10.1002/ajh.24129.
60. Remes K, Anttila P, Silvennoinen R, et al. Real-world treatment outcomes in multiple myeloma: multicenter registry results from Finland 2009–2013. Plos One: 2018; 13: e0208507. doi: 10.1371/journal.pone.0208507.
61. Hájek R, Adam Z, Maisnar V, et al. Souhrn doporučení 2009 Diagnostika a léčba mnohočetného myelomu. Transfuze Hematol Dnes. 2009; 15 (Suppl 2): 1–80.
62. Hájek R, Adam Z, Ščudla V, et al. Souhrn doporučení 2012 Diagnostika a léčba mnohočetného myelomu. Transfuze Hematol Dnes. 2012; 18 (Suppl 1): 1–89.
63. Ščudla V. Současné možnosti léčby mnohočetného myelomu. Remedia. 2009; 19 : 410–419.
64. Hájek R, Maisnar L, Minařík J, et al. Souhrn doporučení 2023 Diagnostika a léčba mnohočetného myelomu. Transfuze Hematol Dnes. 2023; 29 (Suppl 2): 2S1–2S134.
65. Holstein SA, Suman VJ, McCarthy PL. Should overal survival remain an endpoint for multiple myeloma trials? Curr Hematol Malig Rep. 2019; 14 : 31–38. doi: 10.1007/ s11899-019-0495-9.
66. Langseth QO, Myklebust TA, Johannesen TB, Hjertner O, Waage A. Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017. Brit J Haematol. 2020; 191 : 418–425. doi: 10.1111/bjh.16674.
67. Fonseca R, Abouzaid S, Bonafede M, et al. Trends in overal survival and costs of multiple myeloma, 2000-2014. Leukemia. 2017; 31 : 1915–1921. doi: 10.1038/leu.2016.380.
68. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78 : 21–33.
69. Braunlin M, Belani R, Buchanan J, et al. Trends in multiple myeloma treatment landscape and survival: a U. S. analysis using 2011-2019 oncology clinic electronic health record data. Leuk Lymphoma. 2021; 62 : 377–386. doi.org/10.1080/10428194.2020.1827253.
70. Blimark CH, Turesson I, Genell A, et al. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from Swedish myeloma registry. Haematologica. 2018; 103 : 506–513. doi: 10.3324/haematol.2017.178103.
71. Renshaw Ch, Ketley N, Moller H, Davies EA. Trends in the incidence and survival of multiple myeloma in South East England 1985-2004. Br Med Cancer. 2010; 10 : 74–85. doi: 10.1186/1471-2407-10-74.
72. Charlinski G, Tyczynska A, Malecki B, et al. Risk factors and causes for early mortality in patients with newly diagnosed multiple myeloma in a „real world study“: experiences of the Polish Myeloma Group. Pol Arch Intern Med. 2021; 131 : 527–534.
73. Kaya H, Peressini B, Jawed I, et al. Impact of age, race and decade of treatment on overal survival in a critical population analysis of 40,000 multiple myeloma patients. Int J Hem. 2012; 95 : 64–70.
74. Ludwig H, Durie BGM, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. 2008; 111 : 4039–4047. doi: 10.1182/blood-2007-03-081018.
75. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Björkhom M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007; 25 : 1993–1999. doi: 10.1200/JCO.2006.09.0100.
76. Nishimura KK, Barlogie B, van Rhee F, et al. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 2020; 4 : 422–431. doi: 10.1182/blood advances.2019000524.
77. Rodzaj M, Morawska-Krekora A, Razny M, Piatkowska Jakubas B. Survival in multiple myeloma: a real-life single-center study. Acta Haematol Polonica. 2022; 53 : 201–206.
78. Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020; 38 : 1928–1937. doi: 10.1200/JCO.19.02515.
79. Minarik J, Pour L, Latal V, et al. Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group. BMC Cancer. 2025; 25 : 651. doi: 10.1186/s12885-025-14087-y.
80. Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicatibility of the International staging system (ISS): an analysis of the Greek myeloma study group. Leukemia. 2009; 23 : 1152–1157. doi: 10.1038/leu.2008.402.
81. Kristinsson SY, Anderson WF, Landgren O. Improved long-term survival in multiple myeloma up to the age 80 years. Leukemia. 2014; 28 : 1346–1348.
82. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006; 367 : 825–831.
83. Minařík J. Léčba komorbidních a starších nemocných s mnohočetným myelomem. XXXVII. Olomoucké hematologické dny 21. –23. 5. 2025. Sborník abstraktů Olomouckých hematologických dní 2025; Postgraduální sekce 1, s. 51–53.
84. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of randomized controled trial. Blood. 2004; 104 : 3052–3057.
85. Kumar SK, Mikhael JR, Buadi FK et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009; 84 : 1095–1110. doi: 10.4065/mcp.2009.0603.
86. Radocha J, Maisnar V, Zavřelová A, et al. Fifteen years of single center experience with stem cell transplantation for multiple myeloma: a retrospective analysis. Acta Med (Hradec Králové). 2013; 56 : 9–13.
87. O’Shea D, Giles C, Terpos E et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: single-centre experience in 211 patients. Bone Marrow Transpl. 2006; 37 : 731–737. doi: 10.1038/sj.bmt.1705307.
88. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004; 351 : 1860–1973.
89. Van de Velde HJK, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007; 92 : 1399–1406. doi: 10.3324/haematol.11534.
90. Corre J, Perrot A, Hulin C, et al. Improved survival in multiple myeloma during 2005-2009 and 2010-2014 periods. Leukemia. 2021; 35 : 3600–3603. doi: 10.1038/s41375-021-01 250-0.
91. Palumbo A, Anderson K. Multiple myeloma. New Engl J Med. 2011; 364 : 1046–1060.
92. Gulla A, Anderson KC. Multiple myeloma: the (r) evolution of current therapy and a glance into the future. Haematologica. 2020; 105 : 2358–2367. doi: 10.3324/haematol2020.247015.
93. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation in myeloma. N Engl J Med. 2017; 376 : 1311–1320. doi: 10.1056/NEJMoa1611750.
94. Moré S, Corvatta L, Manieri VM, et al. Autologous stem cell transplantation in multiple myeloma: where are we and where do we want to go? Cells. 2022; 11 : 606. doi: 10.3390/cells 11040606.
95. Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017; 3 : 28–35. doi: 10.1001/jamaoncol. 2016.3160.
96. Oivanen TM, Kellokumpu-Yettinen P, Koivisto A-M, Koivunen E, Palva I. Response level and survival after conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study. Eur J Haematol. 1999; 62 : 109–116.
97. Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018; 131 : 301–310. doi: 10.1182/blood-2017-07-795047.
98. Costa LJ, Gonsalves WI, Kumar SK. Early mortality in multiple myeloma. Leukemia. 2015; 29 : 1616–1618. doi: 10.1038/leu.2015.33.
99. Bringhen S, Mateos MV, Zweegman S, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013; 98 : 980–987.
100. Xia J, Wang L, Guo HG. Early mortality in elderly patients undergoing treatment for multiple myeloma in real world practice. J Int Med Res. 2018; 46 : 2230–2237. doi: 10.1177/03000 60518757640.
101. Lenhoff S, Hjorth M, Westin J, et al. Im pact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic myeloma study group. Brit J Haematol. 2006; 133 : 389–396. doi: 10.1111/j.1365-2141. 2006.06042x.
102. Krejčí M, Adam Z, Štork M, Pour Z. Terapie nově diagnostikovaného mnohočetného myelomu pacientů starších 70 let v reálné klinické praxi: retrospektivní analýza dat jednoho centra. XXXVII. Olomoucké hematologické dny 21.–23. 5.2025. Sborník abstraktů Olomoucké hematologické dny 2025, s. 73–74.
103. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007; 370 : 1209–1218.
104. Mateos MV, Ocio EM, Paiva B, et al. Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Rev. 2015; 29 : 387–403.
105. Langren O, Korde N. Treating myeloma: the future is already here! Blood. 2012; 120 : 1754–1756.
106. Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patient entered onto¬ United Kingdom Medical Research Council Trials between 980 and 2002 – Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005; 23 : 9219–9226.
107. Pei H, Ting-Wei L, Jyh-Pyng G, et al. Risk of early mortality in patients with newly diagnosed multiple myeloma. Medicine. 2015; 94: e2305. doi: 10.1097/MD.0000000000002305.
108. Rachet B, Mitry E, Shah A, Cooper N, Coleman MP. Survival from myeloma in England and Wales up to 2001. Br J Cancer. 2008; 99 (Suppl 1): S110–S112. doi: 10.1038/sj.bjc.6604607.
109. Kumar S. Risk of early death in multiple myeloma. Clin Adv Hematol Oncol. 2012; 10 : 172–174.
110. Cheong CHS, Azis TAHTK, Anuar NA, et al. Treatment outcome of newly diagnosed multiple myeloma patients: a retrospective analysis a resource-limited setting. 2021; April. doi: 10.22541/au.161789033.39632939/v1.
111.Kazandjian D. Multiple myeloma epidemiology and survival, a unique malignancy. Semin Oncol. 2016; 43 : 676–681. doi: 10.1053/j.seminoncol.2016.11.004.
112. Engelhardt M, Domm AS, Dold SM, et al. A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Hematologica. 2017; 102 : 910–921. doi: 10.3324/haematol.2016.162693.
113. Sharpley FA, Miller H, Spencer R, et al. Is it time for a more holistic approach to the treatment of multiple myeloma? Hemato. 2021; 2 : 628–634. doi: 10.3390/hemato2040040.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2026 Issue 2
Most read in this issue
- Thrombotic microangiopathy in the maternity ward from the anaesthesiologist‘s perspective – a case study
- Individualization of frontline chronic lymphocytic leukaemia treatment – a comprehensive view on risk stratification in the era of targeted therapy
- Implementation of the SoHO Regulation and the Management of the Plasma Collection System in the Czech Republic – discussion and position of an interdisciplinary panel
- Development of the epidemiological situation of Hodgkin’s lymphoma in the Czech Republic in the period 2000–2019